Spot Trading’s Lexicon Pharmaceuticals LXRX Stock Holding History

Spot Trading’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-12,900	Closed	-$185K	–	3327
2016 Q2	$185K	Buy	+12,900	New	+$175K	﹤0.01%	2264

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Spot Trading's LXRX Position: Q3 2016 in Review

Spot Trading sold out of Lexicon Pharmaceuticals (LXRX) in Q3 2016, closing a stake of 1,800 shares — an estimated $26K sold.

Spot Trading first reported a position in LXRX in Q2 2016 and held it in 1 quarter. The position peaked at $26K in Q2 2016. 144 funds tracked by Wall St. Rank hold LXRX as of Q3 2016.

Spot Trading reported no remaining Lexicon Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
Spot Trading sold 1,800 Lexicon Pharmaceuticals shares in Q3 2016, an estimated $26K.
Spot Trading first reported a position in Lexicon Pharmaceuticals in Q2 2016 and held it in 1 quarter.
Spot Trading's Lexicon Pharmaceuticals position peaked at $26K in Q2 2016.
144 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2016.

Based on Spot Trading's 13F filing for Q3 2016, filed 31 Oct 2016.